688302 Stock Overview
A clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hinova Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.69 |
| 52 Week High | CN¥53.96 |
| 52 Week Low | CN¥22.60 |
| Beta | -0.35 |
| 11 Month Change | 1.54% |
| 3 Month Change | -15.63% |
| 1 Year Change | -42.40% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.65% |
Recent News & Updates
Shareholder Returns
| 688302 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.5% | 4.2% | -0.6% |
| 1Y | -42.4% | -10.6% | -22.0% |
Return vs Industry: 688302 underperformed the CN Pharmaceuticals industry which returned -12.5% over the past year.
Return vs Market: 688302 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 688302 volatility | |
|---|---|
| 688302 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688302 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688302's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 181 | Yuanwei Chen | www.hinovapharma.com |
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer.
Hinova Pharmaceuticals Inc. Fundamentals Summary
| 688302 fundamental statistics | |
|---|---|
| Market cap | CN¥2.54b |
| Earnings (TTM) | -CN¥266.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs 688302 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688302 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥266.00m |
| Earnings | -CN¥266.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 24, 2024
| Earnings per share (EPS) | -2.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 688302 perform over the long term?
See historical performance and comparison